mardi 21 avril 2015

Onco Actu du 21 avril 2015

Lire aussi l'autre billet du jour : Spécial AACR 2

2.5 Etiologie - Gènes

A higher than expected fraction of adolescent osteosarcoma patients carry a gene mutation that is often inherited [National Cancer Institute]

3.1 Tabac

E-cigarette users trying to quit smoking should vape every day, studies suggest [The Guardian]

Type, frequency of e-cigarette use linked to quitting smoking [Reuters]

4.2 Dép., diag. & prono. - Génome

New Genetic Tests for Breast Cancer Hold Promise [NY Times]

Quest Diagnostics, French agency seek to expand breast cancer gene database [Reuters]

4.9 Dép., diag. & prono. - Sein

Federal Panel Revisits Contested Recommendation On Mammograms [NPR]

Task Force Punts On Women Under 50, Jeopardizing Access To Mammograms [Forbes]

Breast Cancer Screening Draft Recommendations [USPSTF]

Mammograms Most Beneficial for Women 50 to 74, Panel Says [Wall Street Journal]

New U.S. mammogram guidelines stick with screening from age 50 [Reuters]

5. Traitements

Foundation Medicine Announces Its Collaboration with the National Cancer Institute on Exceptional Responders Initiative [Foundation Medicine]

Foundation Medicine and NCI form Alliance on Exceptional Responders Initiative [GEN]

Researchers report initial feasibility of identifying patients who are exceptional responders to cancer therapy [National Cancer Institute]

5.2 Pharma

The Battle for Dominance of the Advanced Melanoma Market Continues [The OBR blog]

5.2.1 Pharma - Partenariats

Roche bets $555M on an Indian biotech's immuno-oncology drug [FierceBiotech]

Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Study with Avelumab* in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer [Pfizer]

TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors [Merck]

5.4 Traitements - Economie

Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data [TheStreet]